Management of Opioid Withdrawal

Assessment and Initiation of Management

Assess duration of use and daily dosage to determine dependence risk, as higher doses and longer use correlate with more severe withdrawal, recommended by the Intensive Care Medicine society 1
Recognize that opioid withdrawal may present with symptoms similar to opioid withdrawal, including drug craving, anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, and tachycardia, as suggested by the MMWR Recommendations and Reports guideline 2

Utilize standardized withdrawal assessment tools like the Withdrawal Assessment Tool version 1 (WAT-1) or the Sophia Observation withdrawal Symptoms-scale (SOS) during the tapering process, recommended by the Intensive Care Medicine society 1
Consider buprenorphine/naloxone as a first-line option for patients experiencing significant withdrawal symptoms, as it is more effective than non-opioid management strategies, and preferred over methadone for ED management of opioid withdrawal, as suggested by the Annals of Emergency Medicine guideline 3
Implement a slow, patient-centered taper of 10% per month (or slower), with buprenorphine/naloxone as an alternative for those unable to tolerate tapering, as recommended by the Centers for Disease Control and Prevention (CDC) 4
For patients struggling with taper, consider even slower reductions (5% monthly), as suggested by the Mayo Clinic 5
Schedule frequent follow-ups (at least monthly) during the tapering process, as recommended by the CDC 4

Provide symptomatic treatment, including benzodiazepines for agitation/anxiety, antiemetic medications for nausea, and bolus dose of opioid followed by continuous infusion if needed for pain or respiratory distress, as recommended by the Intensive Care Medicine society 6
Medication-assisted treatment (MAT) with buprenorphine/naloxone is essential, as recommended by the American Society of Addiction Medicine 5

Consider inpatient management for patients at risk of severe withdrawal, with concurrent serious physical or psychiatric disorders, or lacking adequate support, and provide psychosocial support, including involving family members in treatment, encouraging engagement with mutual help groups, and considering referral for more structured psychological interventions, as recommended by the PLoS Medicine guideline 7
Monitor for withdrawal symptoms, assess pain control and functional status regularly, and screen for depression, anxiety, and suicidal ideation, as suggested by the American Academy of Pain Medicine

Monitor for development of depression or psychosis during withdrawal, which may require specialist consultation, and assess for signs of opioid use disorder that may require more intensive treatment, as recommended by the PLoS Medicine guideline 7
Be cautious of abrupt discontinuation of opioids, as it increases risk of withdrawal, relapse, and overdose, as warned by the Mayo Clinic 5
Patients on methadone require special consideration due to long half-life, and are more susceptible to prolonged withdrawal during transition to other treatments, as noted by the CDC
Cold referrals and insufficient monitoring can lead to poor outcomes, and rigid tapering schedules should be individualized based on patient response and tolerance, as recommended by the American Society of Addiction Medicine 5